This study demonstrates the therapeutic potential of DOT1L in the mixed lineage leukemia (MLL) gene rearrangement of leukemia and lays the foundation for future combination therapy in this patient population (Stein et al., 2018) (NCT01684150). Here, KMT2A is linked to leukemia.